Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

NCT04886908 | Completed

• 1 other identifier: CHUB-BOULAKHRIF
• Study Type: observational
• Target: 373
• Locations: 1 country
• Sites: 1

Brief Summary

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity. The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.

Conditions

Skin Cancer

Outcome Measures

Primary Outcomes (19)

• Age

  Age of the patient at the time of diagnose

  5 minutes

• Sex

  Sex of the patient

  5 minutes

• Name of the department in which the patient is followed

  Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital

  5 minutes

• Tumor anatomical location

  Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.

  5 minutes

• Tumor size

  Tumor size in millimeters

  5 minutes

• Laterality

  Laterality: left, right, median

  5 minutes

• Multiple or single tumor

  Multiple or single tumor

  5 minutes

• Primitive tumor or recidive

  Primitive tumor or recidive

  5 minutes

• Risk factor: phototype

  Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.

  5 minutes

• Risk factor: immunosuppression (yes/no)

  Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma

  5 minutes

• Risk factor: keratosis

  Actinic keratosis of the face

  5 minutes

• Risk factor: solar exposition (yes/no)

  Lived in a sunny European country\> 1 year, lived in a sunny country outside Europe\> 1 year, sunbed use\> 1 session, history of solar erythema during childhood.

  5 minutes

• Diagnosis

  Time between the appearance of the tumor and the first consultation

  5 minutes

• Locoregional extension report (yes/no)

  Locoregional extension report (yes/no)

  5 minutes

• Histological diagnosis of the tumor

  Histological diagnosis of the tumor

  5 minutes

• Healthy or invaded margins

  Healthy or invaded margins

  5 minutes

• Superficial or infiltrating tumor

  Superficial or infiltrating tumor

  5 minutes

• Diagnostic method

  Diagnostic method: curettage, punch, biopsy, flattening

  5 minutes

• Surgical management method

  Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen

  5 minutes

Interventions

Data extraction from medical files OTHER

Data extraction from medical files

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Identification of all patients who have undergone surgical excision of benign or malignant facial and/or eyelid tumors over the past 5 years in the Dermatology and/or Ophthalmology Departments of the CHU Saint-Pierre and CHU Brugmann hospitals.

You may qualify if:

• Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

You may not qualify if:

• Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Sponsors & Collaborators

• Brugmann University Hospital: lead

Study Sites (1)

CHU Brugmann

Brussels, 1020, Belgium

Location

MeSH Terms

Conditions

Skin Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Nosria Boulakhrif

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Opthalmology clinic

Study Record Dates

• First Submitted: May 6, 2021
• First Posted: May 14, 2021
• Study Start: February 9, 2021
• Primary Completion: July 28, 2021
• Study Completion: July 28, 2021
• Last Updated: March 8, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)